Provided by Tiger Trade Technology Pte. Ltd.

Aurinia Pharmaceuticals

14.82
+0.84006.01%
Post-market: 14.52-0.2970-2.00%18:29 EDT
Volume:1.48M
Turnover:21.62M
Market Cap:1.97B
PE:7.16
High:14.85
Open:14.16
Low:14.16
Close:13.98
52wk High:16.54
52wk Low:6.83
Shares:132.97M
Float Shares:128.06M
Volume Ratio:1.16
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.07
EPS(LYR):2.07
ROE:59.91%
ROA:11.16%
PB:3.39
PE(LYR):7.16

Loading ...

Aurinia Pharmaceuticals Shares Fall After Leerink Partners Downgrade

MT Newswires Live
·
Dec 04, 2025

Aurinia Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
Dec 03, 2025

Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $16 From $15

MT Newswires Live
·
Dec 03, 2025

Aurinia Pharmaceuticals Inc : Leerink Partners Cuts to Market Perform From Outperform; Raises Target Price to $16 From $15

THOMSON REUTERS
·
Dec 03, 2025

A Look at Aurinia Pharmaceuticals (NasdaqGM:AUPH) Valuation Following Recent Share Price Gains

Simply Wall St.
·
Nov 28, 2025

Aurinia Pharmaceuticals Q3 Operating Income USD 29.745 Million

Reuters
·
Nov 20, 2025

Stock Track | Aurinia Pharmaceuticals Soars 5.04% Following Strong Q3 Results and Raised 2025 Guidance

Stock Track
·
Nov 12, 2025

Aurinia Pharmaceuticals (NasdaqGM:AUPH): Valuation Insights Following Strong Q3 Results and Raised 2025 Guidance

Simply Wall St.
·
Nov 11, 2025

Aurinia Pharmaceuticals Shares Rise After Jefferies Upgrade

MT Newswires Live
·
Nov 08, 2025

Stock Track | Aurinia Pharmaceuticals Soars 9.23% Pre-Market on Jefferies Upgrade and Doubled Price Target

Stock Track
·
Nov 07, 2025

Aurinia Pharmaceuticals Raised to Buy From Hold by Jefferies

Dow Jones
·
Nov 07, 2025

Aurinia Pharmaceuticals upgraded to Buy from Hold at Jefferies

TIPRANKS
·
Nov 07, 2025

Bloom Burton downgrades Aurinia Pharmaceuticals (AUPH) to a Hold

TIPRANKS
·
Nov 06, 2025

Stock Track | Aurinia Pharmaceuticals Plummets 5.05% Following RBC Downgrade to Sector Perform

Stock Track
·
Nov 05, 2025

Aurinia Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital

Dow Jones
·
Nov 05, 2025

RBC Downgrades Aurinia Pharmaceuticals to Sector Perform From Outperform, Raises Price Target to $15 From $9, Keeps Speculative Risk

MT Newswires Live
·
Nov 05, 2025

H.C. Wainwright Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)

TIPRANKS
·
Nov 05, 2025

Aurinia Pharmaceuticals (AUPH) was downgraded to a Hold Rating at RBC Capital

TIPRANKS
·
Nov 05, 2025

Promising Sales and Market Potential of Lupkynis Drive Buy Rating for Aurinia Pharmaceuticals

TIPRANKS
·
Nov 05, 2025

Aurinia Pharmaceuticals Inc : Leerink Partners Raises Target Price to $15 From $12

THOMSON REUTERS
·
Nov 04, 2025